Investigating how albumin and other serum factors affect the accumulation and toxicity of PFAS chemicals.
Official title: The role of albumin and other serum factors in Per- and polyfluoroalkyl substance (PFAS) accumulation and toxicity
Funded at University of Rhode Island · NIH-11108517 · Data updated 2026-11-12
This study is looking into how certain chemicals found in everyday items can build up in our bodies and affect our health, especially focusing on a protein in our blood that might help these chemicals stick around longer, which could lead to problems like liver disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rhode Island NIH-funded |
| Lab location | 1 site (Kingston, United States) |
| Project start | May 13, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $385,219 |
| NIH project number | 1R01ES037367-01 |
| Project ID | NIH-11108517 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with known exposure to PFAS, particularly those experiencing liver-related health issues.
✕Less likely to help
Patients who have not been exposed to PFAS or do not have related health conditions may not benefit from this research.
What this research studies
This research focuses on understanding how per- and polyfluoroalkyl substances (PFAS), commonly found in everyday products, accumulate in the body and their associated health risks. The study will explore the role of albumin, a key protein in the blood, in binding and retaining PFAS, which may contribute to long-term health issues such as liver disease. By examining both in vitro and in vivo models, the research aims to uncover the mechanisms behind PFAS retention and toxicity, potentially identifying additional proteins involved in this process.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and management of PFAS-related health risks, ultimately improving patient outcomes.
How similar studies have gone: While the role of albumin in binding various substances is well-established, this specific investigation into PFAS and its interactions with serum factors is relatively novel.
Where this research is happening
-
University of Rhode Island
Kingston, United States Active
Researchers
- Principal investigator: Slitt, Angela L — University of Rhode Island
- Study coordinator: Slitt, Angela L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.